ZLZhihong Liu

Zhihong Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhihong Liu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Cun Zhao

    College of Animal Science, Inner Mongolia Agricultural University, Hohhot, 010018, China

    1 shared publication
  • Feng Yang

    College of Animal Science, Inner Mongolia Agricultural University, Hohhot, 010018, China; Key Laboratory of mutton sheep genetics and breeding of Ministry of Agriculture, Hohhot, 010018, China

    1 shared publication
  • Jinquan Li

    College of Animal Science, Inner Mongolia Agricultural University, Hohhot, China

    1 shared publication
  • Juntao Guo

    College of Animal Science and Technology, Northwest A&F University, Yangling 712100, China

    1 shared publication
  • Ke Wu

    Division of Cancer Research and Training, Institute for Advanced Biomedical Research, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA

    1 shared publication
  • Rui Li

    Huashan Hospital, Fudan University, Shanghai China

    1 shared publication

Latest Publications

  • Open Access

    Treatment for overactive bladder: A meta-analysis of tibial versus parasacral neuromodulation

    by Zhi-Hong Wang, Zhi-Hong Liu

    Background: The study aimed to assess the efficacy and safety of parasacral neuromodulation (PNS) versus tibial nerve stimulation (TNS) for patients with overactive bladder (OAB). Methods: Databases including PubMed, Embase, clinicalTrial.gov, and Cochrane Library Central Register of Controlled Trials were systematically searched from January 1, 1999 to September 9, 2022. The improvements in a 3-day voiding diary were set as the primary outcomes. Then, the scores of overactive bladder-validated 8-question awareness tool (OAB-V8), King’s health questionnaire (KHQ), and international consultation on incontinence questionnaire overactive bladder (ICIQ-OAB) were also evaluated. Results: Five articles (4 randomized controlled trials [RCTs] and 1 prospective study) including 255 OAB patients were enrolled. Two kinds of neuromodulations had similar performances in the micturition (mean difference [MD] = 0.26, 95% confidence interval [CI]: –0.51 to 1.04, P = .50), urgency episodes (MD = –0.16, 95% CI: –0.64 to 0.31, P = .50), incontinence episodes (MD = 0.09, 95% CI: –0.41 to 0.59, P = .72), as well as in the nocturia episodes (MD = 0.04, 95% CI: –0.45 to 0.52, P = .89). Furthermore, there was no difference regarding ICIQ-OAB scores (P = .83), KHQ (P = .91), and OAB-V8 scores (P = .83). Importantly, included studies reported no adverse events in the 2 groups. Conclusion: TNS and PNS had similar effectiveness for the treatment of OAB, moreover, without any identified adverse events in both groups. However, well-designed RCTs are stilled needed to verify our results.


  • Open Access

    Single-cell sequencing reveals the new existence form of dermal papilla cells in the hair follicle regeneration of cashmere goats

    by Feng Yang, Rui Li, Cun Zhao, Tianyu Che, Juntao Guo, Yuchun Xie, Zhixin Wang, Jinquan Li, Zhihong Liu


  • Open Access

    N-acetyltransferase 1 polymorphism and bladder cancer susceptibility: a meta-analysis of epidemiological studies

    by Ke Wu, Xianding Wang, Zhiyuan Xie, Zhihong Liu, Yiping Lu

    This meta-analysis was conducted to summarize the association between an N-acetyltransferase 1 (NAT1) gene polymorphism and bladder cancer risk. PubMed® and EMBASE databases were searched to identify studies that examined the effect of the NAT1*10 allele on the risk of bladder cancer. Eleven case–control studies, which included 3311 bladder cancer cases and 3906 control subjects, met the inclusion criteria. The pooled analyses based on all studies showed that there was no significant difference in the NAT1*10 allele between bladder cancer cases and controls (odds ratios [OR] 0.96; 95% confidence interval [CI] 0.81, 1.10). When stratifying for race, the results were similar among Caucasians (OR 0.96; 95% CI 0.81, 1.12) and Asians (OR 0.87; 95% CI 0.48, 1.56). No statistical association was found between the NAT1*10 allele and bladder cancer risk upon stratification for smoking status and study design. This meta-analysis suggests that there was no association between the NAT1*10 allele and bladder cancer risk. Further research should focus on other potentially functional genetic polymorphisms.